Pacific Biosciences Of California (PACB) Depreciation & Amortization - Total (2022 - 2026)

Pacific Biosciences Of California has reported Depreciation & Amortization - Total for 5 years, with the latest figure at $2.3 million in Q2 2026.

• On a quarterly basis, Depreciation & Amortization - Total fell 12.71% year-over-year to $2.3 million in Q2 2026; TTM through Jun 2026 was $9.7 million, a 34.48% decrease from a year earlier, with the FY2025 full-year figure at $13.0 million, down 5.8% from the prior year.
• Depreciation & Amortization - Total was $2.3 million for Q2 2026 at Pacific Biosciences Of California, up from $2.2 million in the prior quarter.
• The five-year high for Depreciation & Amortization - Total was $5.1 million in Q1 2025, with the low at $2.2 million in Q1 2026.
• Average Depreciation & Amortization - Total over 5 years is $2.9 million, with a median of $2.8 million recorded in 2023.
• The sharpest annual moves came in 2025 and 2026: Depreciation & Amortization - Total jumped 58.36% in 2025, then sank 57.12% in 2026.
• Over 5 years, Depreciation & Amortization - Total stood at $2.6 million in 2022, then rose by 17.56% to $3.0 million in 2023, then decreased by 4.81% to $2.9 million in 2024, then declined by 4.15% to $2.7 million in 2025, then retreated by 15.57% to $2.3 million in 2026.
• The last three Depreciation & Amortization - Total figures came in at $2.3 million (Q2 2026), $2.2 million (Q1 2026), and $2.7 million (Q4 2025), per Business Quant data.